A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Opicapone (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Neurocrine Biosciences
- 20 Sep 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2018 New trial record